wo recent trials demonstrated that intensive lipid-lowering therapy with statins improved clinical outcomes 1 and reduced the progression of atherosclerosis. 2 Many authorities attributed the greater benefits of intensive statin therapy, as compared with moderate statin therapy, to greater reductions in the levels of atherogenic lipoproteins, particularly low-density lipoprotein (LDL) cholesterol. 3 However, statins have a wide range of biologic effects in addition to lipid lowering, including reductions in the levels of C-reactive protein (CRP), a phenomenon commonly termed a "pleiotropic effect." [4] [5] [6] In both recent comparisons, at the conclusion of the trials, CRP levels were 30 to 40 percent lower after intensive statin therapy than after moderate treatment. 4 This finding raises a provocative scientific question: Do reductions in CRP represent an independent factor influencing the benefits of more intensive statin therapy?
Large observational studies have established a strong relationship between CRP levels and the morbidity and mortality associated with coronary disease. [7] [8] [9] However, the precise mechanism underlying the association between CRP levels and adverse outcomes remains incompletely described. Theoretically, by decreasing the levels of atherogenic lipoproteins, statins could decrease systemic inflammation, thereby reducing CRP levels. An alternative hypothesis proposes that statins have direct antiinflammatory effects, independent of their lipid-lowering capabilities. In this model, CRP plays a more direct role in the pathogenesis of atherosclerosis, and a statin-mediated reduction in inflammation contributes directly to reduced disease activity. Because statins decrease the levels of both LDL cholesterol and CRP, it is difficult to determine whether CRP is an indirect biomarker reflecting the benefits of statins or a direct participant in atherogenesis.
Intravascular ultrasonography is a useful technique for assessing the effect of therapies on the vascular wall, providing a precise and continuous measure of the progression of atherosclerosis. In the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial, intensive therapy with 80 mg of atorvastatin per day slowed the prot Investigators performed intravascular ultrasonography in the longest and least angulated target vessel that met the inclusion criteria. After the adminismethods * Plus-minus values are means ±SD. To convert values for cholesterol to millimoles per liter, multiply by 0.02586. To convert values for triglycerides to millimoles per liter, multiply by 0.01129. † P values were calculated by means of the two-sample t-test. ‡ CRP levels were not available for six patients at baseline or follow-up (one in the pravastatin group and five in the atorvastatin group). The average area of atheroma per cross-section was calculated as follows: S (EEM CSA -LUMEN CSA ), n where EEM CSA is the cross-sectional area of the external elastic membrane, LUMEN CSA is the crosssectional area of the lumen, and n is the number of cross-sections in the pullback. To compensate for pullbacks of differing lengths, the total atheroma volume for each patient was calculated as the average area of atheroma multiplied by the median number of cross-sections in the pullbacks for all patients in the study. The efficacy variable "change in normalized total atheroma volume" (TAV) was calculated as TAV 18 months ¡TAV baseline . The percent atheroma volume (PAV) was calculated with the use of the following formula:
The efficacy variable "change in PAV" was calculated as PAV 18 months -PAV baseline .
laboratory tests
A central laboratory performed all biochemical determinations (Medical Research Laboratory, Highland Heights, Ky.).
statistical analysis
For continuous variables with a normal distribution, means ± SD are reported. For CRP levels, the geometric means and interquartile ranges are reported. Because the ultrasonographic end points were not normally distributed, we applied an analysis-ofcovariance model to rank-transformed data to determine P values. Correlations between variables are described with the use of Spearman rank-correlation coefficients, and multivariate regression analyses based on rank-transformed data were used to obtain partial correlation coefficients adjusted for the effects of covariates. 14 The ultrasonographic variable served as the dependent variable; the independent variables consisted of the change in CRP coupled with the change in non-high-density lipoprotein (non-HDL) cholesterol, LDL cholesterol, or apolipoprotein B-100 (apo B-100). For a further description of bivariate relationships with ultrasonographic end points, we used the locally weighted scatterplot smoothing (LOWESS) technique. 15 This technique is designed to produce a smooth fit to the data and reduces the influence of extreme outliers. Analyses were performed with the use of SAS software, version 6.12.
patient population
Between June 1999 and September 2001, 502 patients were enrolled at 34 U.S. centers and underwent intravascular ultrasonography at both baseline and 18 months of follow-up that could be evaluated (249 in the pravastatin group and 253 in the atorvastatin group). The average age was 56 years, 72 percent were men, 89 percent were white (race was recorded by the study coordinators on the case-report form), 26 percent were current smokers, 69 percent had a history of hypertension, and 19 percent had a history of diabetes. 2 laboratory findings and results of intravascular ultrasonography Table 1 summarizes laboratory values at baseline and at the completion of the study (18 Table 2 summarizes measures of disease burden as determined by intravascular ultrasonography at baseline and the completion of the study for the entire population and the two treatment groups. Both measures of the progression of atherosclerosistotal atheroma volume and percent atheroma volume -reflected a slower rate of progression in the group that received intensive treatment with atorvastatin than in the group that received moderate treatment with pravastatin.
correlation between reductions in lipoprotein and crp
There was a weak but significant correlation between the percent reductions in LDL cholesterol and in CRP levels only for the study group as a whole (r=0.13, P=0.005) -not for the pravastatin group alone (r=¡0.008, P=0.90) or the atorvastatin group alone (r=0.09, P=0.17). Changes in other atherogenic lipoproteins, such as apo B-100 and non-HDL cholesterol, had similarly weak correlations with the reduction in CRP levels in the regression analysis.
effect of changes in crp and lipids on progression Table 3 summarizes the correlations between the changes in the levels of atherogenic lipoproteins, CRP, and HDL cholesterol and the rate of progres-* Values in parentheses are interquartile ranges.
† P values were calculated with the use of the Wilcoxon rank-sum test. ‡ Values were adjusted for pullbacks of different lengths by multiplying the average area of atheroma volume for each patient by the median number of cross-sections in the pullbacks for all patients in the study. The new england journal of medicine 34 sion of atherosclerosis for both end points assessed by means of intravascular ultrasonography. Univariate analysis revealed significant correlations between ultrasonographic measures of disease progression and laboratory measures of atherogenic lipoproteins, including LDL cholesterol, apo B-100, and non-HDL cholesterol. The percent change in the LDL cholesterol level had the closest correlation with progression, with a correlation coefficient of 0.12 for total atheroma volume (P=0.005) and of 0.14 for percent atheroma volume (P=0.002).
The correlations between the reduction in CRP levels and the rates of progression on intravascular ultrasonography were also significant and similar in strength to the relationships observed for the atherogenic lipoproteins. Univariate analysis yielded a correlation coefficient of 0.11 for both total and percent atheroma volume (P=0.02 and P=0.01, respectively). Most correlations between the rates of progression on ultrasonography and the percent change in non-HDL cholesterol, LDL cholesterol, and CRP levels remained significant on multivariate analysis but were weaker than those obtained by univariate analyses (Table 3) .
As shown in Figure 1 , greater reductions in LDL cholesterol levels were associated with slower rates of progression on intravascular ultrasonography. Figure 2 shows this same relationship for the reduction in CRP levels. Patients with the largest reductions in CRP levels had regression of atheroma, as evidenced by progression rates of less than zero. Table 4 shows the rates of progression of atherosclerosis on ultrasonography for subgroups defined according to whether the reductions in LDL cholesterol or CRP levels were greater than or less than the median decreases. For both efficacy measures, the highest rates of progression were in the subgroup in which decreases in both LDL cholesterol and CRP levels were less than the median. Significantly lower progression rates were observed in the subgroup with decreases in both LDL cholesterol and CRP levels that were greater than the median (P=0.001 for both efficacy measures).
Epidemiologic evidence has established a strong relationship between elevated levels of atherogenic lipoproteins, particularly LDL cholesterol, and the risk of death and complications from cardiovascular causes. Placebo-controlled trials of statins have demonstrated that pharmacologic therapies that reduce LDL cholesterol levels also proportionally decrease cardiovascular risk. [16] [17] [18] [19] Accordingly, the clinical benefits of statin therapy have largely been attributed to reductions in the levels of atherogenic lipoproteins. However, observational studies have also established a strong relationship between the levels of CRP, the most stable and reliable laboratory measure of systemic inflammation, and adverse discussion * Values are Spearman rank-correlation coefficients. Since statins reduce the levels of both LDL cholesterol and CRP, it is difficult to determine the relative contribution of the reduction in each of these biomarkers to the observed clinical benefits. We sought to close this gap in knowledge by analyzing the correlation among lipid levels, CRP levels, and the rate of progression of atherosclerosis, using intravascular ultrasonography to measure disease progression in patients who were being treated with statins. 2 Intravascular ultrasonography is a useful technique for assessing the effect of therapies on the vascular wall, providing a precise and continuous measure of disease progression. 20 In the REVERSAL trial, intensive therapy with 80 mg of atorvastatin per day slowed the rate of progression of atherosclerosis more than did moderate treatment with 40 mg of pravastatin per day. Because we studied two different intensities of statin therapy, we evaluated a broad range of reductions in LDL cholesterol and CRP, permitting a post hoc analysis of the relationship between these two biomarkers and the rate of progression of atherosclerosis across a clinically important range of values.
Correlation analysis revealed that reductions in the levels of atherogenic lipoproteins were not closely correlated with reductions in CRP levels. There was a weak but significant correlation between the reduction in LDL cholesterol levels and the reduction in CRP levels for the overall group of 502 patients (r=0.13, P=0.005), but not in either treatment group alone. These data demonstrate that statin-mediated reductions in CRP are largely unrelated to the decrease in LDL cholesterol levels. These findings confirm the work of other investigators and strongly suggest that the statin-mediated reduction in CRP is unlikely to be a secondary consequence of a reduction in LDL cholesterol but, rather, is potentially mediated by independent pathways. 21 Analysis of the relationship among lipoprotein levels, CRP levels, and the rate of progression of atherosclerosis yielded particularly informative results. Reductions in both LDL cholesterol and CRP levels were significantly correlated to the rate of progression. In univariate analyses, both ultrasonographic measures of progression -the change in the normalized total atheroma volume and the change in percent atheroma volume -correlated significantly with the reduction in the levels of atherogenic lipoproteins, including LDL cholesterol, non-HDL cholesterol, and apo B-100. The closest correlation was between the LDL cholesterol level and the percent atheroma volume (r=0.14, P=0.002). However, similar correlations were observed for the relationship between the reduction in CRP levels and the rate of progression on intravascular ultrasonography (r=0.11, P=0.01). Substituting non-HDL cholesterol for LDL cholesterol, to account for the broad range of atherogenic lipoproteins, did not increase the correlation. Since the levels of both CRP and LDL cholesterol showed relatively weak correlations with the ultrasonographic end points (r values of 0.11 to 0.14), this analysis demonstrates that biomarkers can account for only a small fraction of the observed progression rate.
To determine whether the reduction in CRP levels represented an independent factor influencing the progression of atherosclerosis, we adjusted the CRP correlations for the effects of atherogenic lipoproteins. In this multivariate analysis, CRP remained significant in most analyses, regardless of which measure of atherogenic lipoproteins was used -LDL cholesterol, apo B-100, or non-HDL cholesterol. Patients with reductions in the levels of both LDL cholesterol and CRP that were greater than the median reduction had significantly lower progression rates than patients in whom the reductions were less than the median decrease (P=0.001). These data provide evidence that the reduction in CRP levels plays an independent role in the beneficial effects of statins on the progression of coronary atherosclerosis.
Since measures of progression reflected by intravascular ultrasonography are not normally distributed, we used LOWESS methods to illustrate the relationships between the reductions in LDL cholesterol and CRP levels and the rates of progression determined by ultrasonography ( Fig. 1 and 2) . These plots demonstrated a continuous relationship between the magnitude of reduction in either LDL cholesterol or CRP levels and the rates of progression of atherosclerosis for both measures of efficacy. Atherosclerosis regressed in patients with the greatest reduction in CRP levels, but not in those with the greatest reduction in LDL cholesterol levels. Although the data are not provided in this article, LOWESS plots showed slower rates of progression in the intensively treated atorvastatin subgroup across a broad range of reductions in lipids and CRP. The slower rate of progression in the atorvastatin group for any magnitude of reduction in LDL cholesterol levels can be partially explained by the additional effects of treatment on the reduction in CRP levels, just as the differences in the CRP plots can be partially explained by the additional reduction in LDL cholesterol levels effected by atorvastatin therapy. Thus, the effects of the reductions in both LDL cholesterol and CRP levels must be considered to explain the observed differences in progression between atorvastatin and pravastatin treatment.
Our findings have important implications for understanding the pathogenesis of the progression of atherosclerosis and the mechanism of benefit of statin therapy. The Pravastatin or Atorvastatin and Infection Therapy (PROVE IT) trial demonstrated improved outcomes 1 and the REVERSAL trial demonstrated reduced rates of progression of atherosclerosis 2 after intensive, as compared with moderate, statin therapy. Although a single trial had previously shown that the effects of statins are evident within 16 weeks, 22 the rapidity of the divergence in results between the treatment groups in both trials was unexpected. 4 In most earlier placebo-controlled trials, differences between statins and placebo were not evident for the first two years after randomization. [16] [17] [18] However, in both the REVERSAL and PROVE IT trials, CRP levels were 30 to 40 percent lower at the conclusion of the trial in the intensively treated patients than in the group that received moderate treatment, which may ex- plain the magnitude and unexpectedly rapid divergence of outcomes reported by Ridker et al. elsewhere in this issue of the Journal . 23 Our findings are consistent with a variety of experimental observations that suggest a direct role for CRP in the pathogenesis of atherosclerosis. CRP renders oxidized LDL more susceptible to uptake by macrophages, induces the expression of vascular-cell adhesion molecules, stimulates the production of tissue factor, and impairs the production of nitric oxide. [24] [25] [26] [27] Children with elevated CRP levels have increased carotid intimal medial thickness and reduced vasodilatation mediated by brachial-artery flow. 28 A recent study suggested that the presence of above-average levels of CRP attenuates the benefits of intensive statin therapy with respect to the carotid intimal media thickness. 29 Evidence of a dual mechanism of benefit for statins -lipid lowering and a reduction in inflammation -has important implications for current and future treatment of atherosclerosis. Current guidelines emphasize the use of lipid-lowering therapies to reach target levels of LDL cholesterol, non-HDL cholesterol, or both. However, individual agents differ in their ability to reduce the levels of inflammatory biomarkers. Accordingly, our study raises the provocative question of whether the effects of statins on CRP, as well as LDL cholesterol, should be considered in decisions regarding therapy.
Our study has important limitations. It is a hypothesis-generating post hoc analysis examining the effect of a single inflammatory marker on disease progression, not morbidity or mortality. Nonetheless, our findings suggest that the level of CRP may ultimately represent an important therapeutic target. We do not believe that these data are sufficient to recommend routine serial measurement of CRP in order to modulate statin therapy, but further study is warranted. An ongoing clinical trial is assessing the use of CRP levels to guide therapy in patients who do not have elevated LDL cholesterol levels. 30 Since approaches to the reduction of LDL cholesterol levels that do not involve statins have uncertain antiinflammatory effects, the ability of such therapies to improve the outcome requires testing in clinical trials. 31
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